Genprex Inc GNPX

NAS: GNPX | ISIN: US3724461047 14/11/2024

1,640 USD (+2,50%)

(+2,50%) 14/11/2024

Grafiek Genprex Inc

Grafiek Genprex Inc

1 dag1d 2,50%
1 week1w 5,81%
1 maand1m 388,53%
3 maanden3m 151,57%
6 maanden6m -34,53%
1 jaar1j 530,77%
5 jaar5j 307,15%

Genprex Inc in het nieuws

Toon enkel gratis nieuws

9 september 2024 · Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics · Persbericht

4 september 2024 · Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes · Persbericht

3 september 2024 · Genprex to Present and Participate at Upcoming September Investor and Industry Conferences · Persbericht

15 augustus 2024 · Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials · Persbericht

14 augustus 2024 · Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer · Persbericht

13 augustus 2024 · Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers · Persbericht

8 augustus 2024 · Genprex to Present at the August Sidoti Microcap Conference · Persbericht

27 juni 2024 · Genprex Issues Stockholder Letter and Provides 2024 Corporate Update · Persbericht

30 mei 2024 · Genprex to Present at the 2024 BIO International Convention · Persbericht

14 mei 2024 · Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer · Persbericht

Profiel Genprex Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.genprex.com

Hoofdzetel: Austin, Texas Verenigde Staten

CEO: J. Rodney Varner

Werknemers: 26

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe